Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Do not aspirate for subcutaneous injections
These outcomes align with findings in emerging research
The tirzepatide shortage resolved on December 19, 2024
What This Means for Future Treatment Although retrospective, this evidence highlights the strong potential benefit of GLP-1 RAs in MPNs and MDS
The glucose lowering version of tirzepatide (Mounjaro) became a mega blockbuster in its third year on the market, becoming Lillys first product with annual sales exceeding USD 10 billion
Timeline of Regulatory Milestones 2005: Exenatide (Byetta): First GLP-1 agonist approved, twice-daily injections 2010: Liraglutide (Victoza): Longer-lasting, once-daily injection 2014: Dulaglutide (Trulicity): Once-weekly injection arrives 2017: Semaglutide (Ozempic): First once-weekly injection for diabetes with powerful weight-loss effects 2019: Oral semaglutide (Rybelsus): First GLP-1 pill makes it past the stomachs defenses 2021: High-dose semaglutide (Wegovy): FDA approval for obesity treatment 2022: Tirzepatide (Mounjaro): First dual GLP-1/GIP agonist for diabetes 2023: Tirzepatide (Zepbound): Expanded approval for obesity 20232024 : Widespread shortages: Skyrocketing demand for GLP-1s leads to limited availability The shortage that began in late-2023, driven by soaring off-label demand and supply-chain bottlenecks left millions of patients unable to fill even maintenance scripts
